{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:56:45Z","timestamp":1781719005664,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Gilead Sciences, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13318-026-01007-z","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T02:01:03Z","timestamp":1778292063000},"page":"433-440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics, Safety, and Tolerability of Obeldesivir in Healthy Japanese and White\u00a0Participants"],"prefix":"10.1007","volume":"51","author":[{"given":"Chi-Chi","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Corpus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiannis","family":"Koullias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzelena","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"17","key":"1007_CR1","doi-asserted-by":"publisher","first-page":"11701","DOI":"10.1021\/acs.jmedchem.3c00750","volume":"66","author":"RL Mackman","year":"2023","unstructured":"Mackman RL, Kalla RV, Babusis D, Pitts J, Barrett KT, Chun K, et\u00a0al. Discovery of GS-5245 (obeldesivir), an oral prodrug of nucleoside GS-441524 that exhibits antiviral efficacy in SARS-CoV-2-infected African green monkeys. J Med Chem. 2023;66(17):11701\u201317. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00750.","journal-title":"J Med Chem"},{"issue":"5","key":"1007_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40262-021-00984-5","volume":"60","author":"R Humeniuk","year":"2021","unstructured":"Humeniuk R, Mathias A, Kirby BJ, Lutz JD, Cao H, Osinusi A, et\u00a0al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesivir, a SARS-CoV-2 replication inhibitor. Clin Pharmacokinet. 2021;60(5):569\u201383. https:\/\/doi.org\/10.1007\/s40262-021-00984-5.","journal-title":"Clin Pharmacokinet"},{"issue":"748","key":"1007_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj4504","volume":"16","author":"DR Martinez","year":"2024","unstructured":"Martinez DR, Moreira FR, Catanzaro NJ, Diefenbacher MV, Zweigart MR, Gully KL, et\u00a0al. The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses. Sci Transl Med. 2024;16(748):eadj4504. https:\/\/doi.org\/10.1126\/scitranslmed.adj4504.","journal-title":"Sci Transl Med"},{"issue":"8","key":"1007_CR4","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1021\/acs.jmedchem.1c00071","volume":"64","author":"RL Mackman","year":"2021","unstructured":"Mackman RL, Hui HC, Perron M, Murakami E, Palmiotti C, Lee G, et\u00a0al. Prodrugs of a 1\u2032-CN-4-Aza-7,9-dideazaadenosine C-nucleoside leading to the discovery of remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the African green monkey model of RSV. J Med Chem. 2021;64(8):5001\u201317. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00071.","journal-title":"J Med Chem"},{"issue":"6688","key":"1007_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk6176","volume":"383","author":"RW Cross","year":"2024","unstructured":"Cross RW, Woolsey C, Chu VC, Babusis D, Bannister R, Vermillion MS, et\u00a0al. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus. Science. 2024;383(6688):eadk6176. https:\/\/doi.org\/10.1126\/science.adk6176.","journal-title":"Science"},{"issue":"4","key":"1007_CR6","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/s41591-025-03496-y","volume":"31","author":"RW Cross","year":"2025","unstructured":"Cross RW, Woolsey C, Prasad AN, Borisevich V, Agans KN, Deer DJ, et\u00a0al. Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates. Nat Med. 2025;31(4):1303\u201311. https:\/\/doi.org\/10.1038\/s41591-025-03496-y.","journal-title":"Nat Med"},{"key":"1007_CR7","unstructured":"Pitts J, Zamora JLR, Manhas S, Aeschbacher T, Chan J, Cutillas V, et\u00a0al. Obeldesivir exhibits broad anti-RSV activity and a high barrier to resistance in vitro and is efficacious in a non-human primate challenge model of RSV infection. Presented at: Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID); 11\u201315 April 2025; Vienna, Austria. Poster EO288."},{"issue":"11","key":"1007_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adw0659","volume":"11","author":"C Woolsey","year":"2025","unstructured":"Woolsey C, Cross RW, Chu VC, Prasad AN, Agans KN, Borisevich V, et\u00a0al. The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection. Sci Adv. 2025;11(11):eadw0659. https:\/\/doi.org\/10.1126\/sciadv.adw0659.","journal-title":"Sci Adv"},{"issue":"5","key":"1007_CR9","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1016\/S1473-3099(23)00515-7","volume":"24","author":"G Cuomo-Dannenburg","year":"2024","unstructured":"Cuomo-Dannenburg G, McCain K, McCabe R, Unwin HJT, Doohan P, Nash RK, et\u00a0al. Marburg virus disease outbreaks, mathematical models, and disease parameters: a systematic review. Lancet Infect Dis. 2024;24(5):e307\u201317. https:\/\/doi.org\/10.1016\/S1473-3099(23)00515-7.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1007_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04123-w","volume":"23","author":"G Absolomon","year":"2025","unstructured":"Absolomon G, Brent CR, Nyabyenda EC, Mwiza K, Irakiza P, Chiwandire Z, et\u00a0al. Marburg virus disease in Rwanda: an observational study of the first 10 days of outbreak response, clinical interventions, and outcomes. BMC Med. 2025;23(1):292. https:\/\/doi.org\/10.1186\/s12916-025-04123-w.","journal-title":"BMC Med"},{"issue":"1","key":"1007_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jiph.2023.10.020","volume":"17","author":"J Izudi","year":"2024","unstructured":"Izudi J, Bajunirwe F. Case fatality rate for Ebola disease, 1976\u20132022: a meta-analysis of global data. J Infect Public Health. 2024;17(1):25\u201334. https:\/\/doi.org\/10.1016\/j.jiph.2023.10.020.","journal-title":"J Infect Public Health"},{"key":"1007_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(25)00238-5","author":"O Ogbuagu","year":"2025","unstructured":"Ogbuagu O, Goldman JD, Gottlieb RL, Singh U, Shinkai M, Acloque G, et\u00a0al. Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Infect Dis. 2025. https:\/\/doi.org\/10.1016\/S1473-3099(25)00238-5.","journal-title":"Lancet Infect Dis"},{"key":"1007_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf406","author":"A Streinu-Cercel","year":"2025","unstructured":"Streinu-Cercel A, Castagna A, Chang SC, Chen YS, Koullias Y, Mozaffarian A, et\u00a0al. Efficacy and safety of obeldesivir in high-risk nonhospitalized patients with COVID-19 (BIRCH): a phase 3, randomized, double-blind, placebo-controlled study. Clin Infect Dis. 2025. https:\/\/doi.org\/10.1093\/cid\/ciaf406.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1007_CR14","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/cpt.3575","volume":"117","author":"CC Peng","year":"2025","unstructured":"Peng CC, Humeniuk R, Raut A, Kwan A, Mak L, Stacom C, et\u00a0al. Clinical evaluation of drug\u2013drug interactions with obeldesivir, an orally administered antiviral agent. Clin Pharmacol Ther. 2025;117(5):1403\u201312. https:\/\/doi.org\/10.1002\/cpt.3575.","journal-title":"Clin Pharmacol Ther"},{"key":"1007_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2147\/MDER.S295893","volume":"14","author":"E Abu-Haydar","year":"2021","unstructured":"Abu-Haydar E, Katuntu D, Bauer J, Wollen A, Eisenstein M, Sherman-Konkle J, et\u00a0al. User-centered design: developing the RELI Delivery System \u2013 A low-cost, non-electric, pneumatic infusion pump. Med Devices (Auckl). 2021;14:185\u201392. https:\/\/doi.org\/10.2147\/MDER.S295893.","journal-title":"Med Devices (Auckl)."},{"issue":"5","key":"1007_CR16","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/cpt.3337","volume":"116","author":"O Anoshchenko","year":"2024","unstructured":"Anoshchenko O, Abdelghany M, Lichtman A, Duan R, Chen H, Shaik NA, et\u00a0al. Pharmacokinetics, mass balance, safety, and tolerability of obeldesivir in healthy participants. Clin Pharmacol Ther. 2024;116(5):1231\u20139. https:\/\/doi.org\/10.1002\/cpt.3337.","journal-title":"Clin Pharmacol Ther"},{"key":"1007_CR17","unstructured":"Salgado E, Amini E, Caro L, Wang X. A population pharmacokinetic model of obeldesivir in healthy volunteers and patients with COVID-19. Presented at: 33rd Meeting of the Population Approach Group Europe (PAGE); 4\u20136 June 2025; Thessaloniki, Greece. Poster 472."},{"key":"1007_CR18","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Laboratory evaluation of kidney disease\u2014Estimated glomerular filtration rate calculators. https:\/\/www.niddk.nih.gov\/health-information\/professionals\/clinical-tools-patient-management\/kidney-disease\/laboratory-evaluation\/estimated-gfr-calculators. Accessed 17 June 2025."},{"issue":"5","key":"1007_CR19","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/cts.12840","volume":"13","author":"R Humeniuk","year":"2020","unstructured":"Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G, Chng E, et\u00a0al. Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects. Clin Transl Sci. 2020;13(5):896\u2013906. https:\/\/doi.org\/10.1111\/cts.12840.","journal-title":"Clin Transl Sci"},{"key":"1007_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2021.114118","volume":"617","author":"D Xiao","year":"2021","unstructured":"Xiao D, Kh JL, Tarnowski T, Humeniuk R, German P, Mathias A, et\u00a0al. Validation of LC\u2013MS\/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies. Anal Biochem. 2021;617:114118. https:\/\/doi.org\/10.1016\/j.ab.2021.114118.","journal-title":"Anal Biochem"},{"issue":"3","key":"1007_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/cpt.61","volume":"97","author":"A Ramamoorthy","year":"2015","unstructured":"Ramamoorthy A, Pacanowski MA, Bull J, Zhang L. Racial\/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther. 2015;97(3):263\u201373. https:\/\/doi.org\/10.1002\/cpt.61.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1007_CR22","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40261-022-01181-3","volume":"42","author":"P Fouqueray","year":"2022","unstructured":"Fouqueray P, Chevalier C, Bolze S. Pharmacokinetics of imeglimin in Caucasian and Japanese healthy subjects. Clin Drug Investig. 2022;42(9):721\u201332. https:\/\/doi.org\/10.1007\/s40261-022-01181-3.","journal-title":"Clin Drug Investig"},{"issue":"12","key":"1007_CR23","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/psp4.13224","volume":"13","author":"O Majid","year":"2024","unstructured":"Majid O, Cao Y, Willis BA, Hayato S, Takenaka O, Lalovic B, et\u00a0al. Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer\u2019s disease. CPT Pharmacomet Syst Pharmacol. 2024;13(12):2111\u201323. https:\/\/doi.org\/10.1002\/psp4.13224.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"5","key":"1007_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40261-020-00910-w","volume":"40","author":"M Shibata","year":"2020","unstructured":"Shibata M, Hatta T, Saito M, Toyoshima J, Kaneko Y, Oda K, et\u00a0al. Pharmacokinetics, pharmacodynamics, and safety of peficitinib (ASP015K) in healthy male Caucasian and Japanese subjects. Clin Drug Investig. 2020;40(5):469\u201384. https:\/\/doi.org\/10.1007\/s40261-020-00910-w.","journal-title":"Clin Drug Investig"},{"key":"1007_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70065","author":"K Fukuhara","year":"2025","unstructured":"Fukuhara K, Tanetsugu Y, Wada S, Muto C, Kawai N. Evaluation of characteristics and ethnic sensitivity for FDA-approved drugs with racial and ethnic differences in pharmacokinetics, safety, and efficacy. J Clin Pharmacol. 2025. https:\/\/doi.org\/10.1002\/jcph.70065.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1007_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.890","volume":"9","author":"O Olafuyi","year":"2021","unstructured":"Olafuyi O, Parekh N, Wright J, Koenig J. Inter-ethnic differences in pharmacokinetics\u2014Is there more that unites than divides? Pharmacol Res Perspect. 2021;9(6):e00890. https:\/\/doi.org\/10.1002\/prp2.890.","journal-title":"Pharmacol Res Perspect"},{"key":"1007_CR27","unstructured":"ClinicalTrials.gov. Study of obeldesivir in nonhospitalized participants with COVID-19 (OAKTREE). ClinicalTrials.gov Identifier: NCT05715528. https:\/\/clinicaltrials.gov\/study\/NCT05715528?tab=results. Accessed 2 Mar 2026."},{"key":"1007_CR28","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Ethnic factors in the acceptability of foreign clinical data E5(R1). ICH Harmonised Tripartite Guideline. https:\/\/ich.org\/page\/efficacy-guidelines. Accessed 2 March 2026."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01007-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01007-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01007-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:25:31Z","timestamp":1781717131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01007-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01007-z","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees and stockholders of Gilead Sciences, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Gilead Sciences shares anonymized individual patient data upon request or as required by law or regulation with qualified external researchers on the basis of submitted curriculum vitae and reflecting non-conflict of interest. The request proposal must also include a statistician. Approval of such requests is at Gilead Sciences\u2019 discretion and is dependent on the nature of the request, the merit of the research proposed, the availability of the data, and the intended use of the data. Data requests should be sent to datasharing@gilead.com.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The study protocol was approved by the study site ethics committee on 26 May 2023 (approval no.: Pro00071895), and the study was conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: C.C.P.; data curation: C.C.P., E.S., S.D., N.Q., and Y.K.; formal analysis: C.C.P., E.S., S.D., N.Q., and Y.K.; methodology: C.C.P., E.S., S.D., N.Q., and Y.K.; project administration: J.C.; resources: J.C.; supervision: C.C.P., J.C., and L.C.; writing\u2014review and editing: all authors.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}